Home/Lineage Cell Therapeutics/Jennifer Bahr-Davidson, Ph.D.
JB

Jennifer Bahr-Davidson, Ph.D.

Vice President of Technical Operations

Lineage Cell Therapeutics

Lineage Cell Therapeutics Pipeline

DrugIndicationPhase
OPC1Acute Spinal Cord InjuryPhase 1/2a
OpRegenGeographic Atrophy secondary to Age-related Macular DegenerationPhase 1/2a
ANP1Sensorineural Hearing LossPreclinical
VAC2Non-small Cell Lung CancerPhase 1